We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.2282 | -0.25% | 90.6518 | 90.65 | 90.82 | 90.99 | 89.38 | 90.72 | 60,528 | 15:20:38 |
From May 2019 to May 2024
By Matt Grossman
Pfizer Inc. and BioNTech shares climbed in premarket trading Wednesday morning following the companies' receipt of an emergency-use authorization in the U.K. for their jointly created Covid-19 vaccine.
Pfizer shares rose about 4% to $40.97. BioNTech American depositary receipts traded 7.6% higher at $122.63.
The U.K. authorization follows clinical trials that have showed the vaccine to be 95% effective at preventing symptomatic Covid-19, according to the companies. The vaccine uses a new technology based on messenger RNA to trigger the immune system to guard against infection with the coronavirus.
The Food and Drug Administration is considering the vaccine for a similar authorization in the U.S. It could be approved in the U.S. before the end of the year.
The U.K. said it will use its initially limited supply of the Pfizer and BioNTech product to begin vaccinating nursing-home residents and staff.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
December 02, 2020 07:04 ET (12:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
